Please ensure Javascript is enabled for purposes of website accessibility

Novavax Wins COVID-19 Vaccine Contract With U.S. Department of Defense

By Keith Speights – Jun 5, 2020 at 10:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In return for up to $60 million in funding, the biotech will deliver 10 million doses of NVX-CoV2373 to the military in 2020.

Novavax (NVAX -1.99%) announced on Thursday evening that the U.S. Department of Defense (DoD) has awarded it a contract to supply a large quantity of its vaccine candidate NVX-CoV2373 to the military. The biotech is currently in the phase 1 stage of clinical trials evaluating the vaccine against SARS-CoV-2, the coronavirus that causes COVID-19

The Department of Defense will provide Novavax up to $60 million to support the domestic manufacture of several components of the experimental COVID-19 vaccine. In return, Novavax will supply 10 million doses of NVX-CoV2373 to the DoD this year. These doses could be used in phase 2/3 clinical trials, but could also be administered to military personnel and their families if the Food and Drug Administration grants the vaccine candidate an Emergency Use Authorization (EUA).

Coronavirus vaccine bottles

Image source: Getty Images.

The contract requires Novavax to work with a U.S.-based biologics contract development manufacturing organization (CDMO) to produce the antigen used in NVX-CoV2373. Novavax will also work with U.S.-based CDMOs to manufacture its proprietary Matrix-M adjuvant, which will be administered with NVX-CoV2373. Adjuvants are additives designed to enhance vaccines' effectiveness by increasing the immune response they generate.

Novavax initiated a phase 1 clinical study of NVX-CoV2373 on May 26. The biotech anticipates reporting preliminary results from this study in July. If those results are positive, Novavax intends to quickly advance the COVID-19 vaccine candidate into phase 2 testing. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.20 (-1.99%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
103%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.